miR-941 in extracellular vesicles confers anlotinib resistance via Keap1/Nrf2 axis and represents a therapeutic target in non-small cell lung cancer
{{output}}
Background: Anlotinib is a multitargeted tyrosine kinase inhibitor for the treatment of advanced non-small cell lung cancer (NSCLC), though its therapeutic efficacy is constrained by acquired resistance. Although elevated extrace... ...
